Show simple item record

dc.contributor.authorHammond, Emma
dc.contributor.authorAlmeida, Coral-Ann
dc.contributor.authorMamotte, Cyril
dc.contributor.authorNolan, David
dc.contributor.authorPhillips, Elizabeth
dc.contributor.authorSchollaardt, Tineke Asma
dc.contributor.authorGill, M. John
dc.contributor.authorAngel, Jonathan B.
dc.contributor.authorNeurath, Doris
dc.contributor.authorLi, Jianping
dc.contributor.authorGiulivi, Tony
dc.contributor.authorMcIntyre, Cathy
dc.contributor.authorKoultchitski, Galina
dc.contributor.authorWong, Betty
dc.contributor.authorReis, Marciano
dc.contributor.authorRachlis, Anita
dc.contributor.authorCole, David E.
dc.contributor.authorChew, Choo Beng
dc.contributor.authorNeifer, Stefan
dc.contributor.authorLalonde, Richard
dc.contributor.authorRogers, Michel
dc.contributor.authorJeanneau, Annie
dc.contributor.authorMallal, Simon
dc.identifier.citationHammond, Emma and Almeida, Coral-Ann and Mamotte, Cyril and Nolan, David and Phillips, Elizabeth and Schollaardt, Tineke Asma and Gill, M. John et al. 2007. External quality assessment of HLA-B*5701 reporting: An international multicentre survey. Antiviral Therapy. 12 (7): 1027-1032.

Objectives: HLA-B*5701 strongly predicts abacavir hypersensitivity (HSR), but implementation of effective routine screening into clinical practice requires testing be practical and accurate. We tested the proficiency of HLA-B*5701 typing among laboratories using sequence specific primer PCR. Design and methods: DNA panels (1 and 2) were distributed to seven laboratories (A to G) for blinded typing of the HLA-B*5701 allele. Panel 1 (n=10 samples; n=7 laboratories) included 3 positives and other closely related B17 subtypes (B*5702, B*5703, B*5704 and B*5801). Panel 2 (n=96 samples; n=4 laboratories) included 36 positives among a broad spectrum of other B alleles. Two laboratories (A and B) also submitted 96 routine samples, typed by the same methodology, to the reference centre for additional analysis by sequence-based typing. Results: All laboratories correctly typed panel 1 for HLA-B*5701 carriage. Laboratories A, B and C identified HLA-B*5701 alleles in panel 2 with 100% sensitivity and 100% specificity. Laboratory D reported one false negative, reportedly due to a sampling error. The results obtained for routine samples typed by laboratories A and B and those generated by the reference laboratory using sequencing were fully concordant. Conclusions: Detection of HLA-B*5701 alleles among laboratories was 100% specific and 99.4% sensitive, indicating that participating HIV testing laboratories were currently offering effective primary screening to identify individuals at high risk of abacavir HSR. Accurate reporting of HLA-B*5701 status is critical for the safe administration of this drug and participation in quality assurance programmes by all sites who report HLA-B*5701 status should be promoted.

dc.publisherInternational Medical Press
dc.titleExternal quality assessment of HLA-B*5701 reporting: An international multicentre survey
dc.typeJournal Article
dcterms.source.issn1359 6535
dcterms.source.titleAntiviral Therapy
curtin.accessStatusFulltext not available
curtin.facultyDivision of Health Sciences
curtin.facultySchool of Biomedical Sciences

Files in this item


This item appears in the following Collection(s)

Show simple item record